Shire (SHP) Stock Rating Reaffirmed by Citigroup


's stock had its "buy" rating reiterated by equities researchers at Citigroup in a research report issued to clients and investors on Wednesday. They currently have a GBX 5,500 price target on the biopharmaceutical company's stock.



from Biotech News